0
Editor's Correspondence |

Osteoporosis and Fracture Risk Prevention in Long-term Glucocorticoid Therapy

Edin Karcic, MD; Arsad A. Karcic, MD
Arch Intern Med. 2001;161(14):1780. doi:.
Text Size: A A A
Published online

Extract

With great interest, we read the article on long-term corticosteroid therapy by Naganathan et al,1 who reported an increased risk of vertebral deformity associated with the combination of increased age and glucocorticoid use. Osteoporosis and fractures are a major concern in patients receiving long-term glucocorticoid treatment (≥3 months). To estimate which proportion of our patients were receiving osteoporosis prevention during long-term glucocorticoid therapy, we randomly selected the charts of 51 patients who continuously received steroids for at least 3 months (between February 1997 and July 1999). The patients were either inpatients or outpatients (seen in the clinics or in the emergency department) who received steroids either orally or by injection. Any preventive measure (ranging from simple calcium supplementation to hormone replacement therapy) was qualified as "receiving some osteoporosis prevention," as opposed to receiving "no osteoporosis prevention whatsoever." Of the 51 patients in this retrospective study, 35 (68%) were female and 16 (32%) were male. The patients ranged in age from 10 to 95 years (mean age, 61 years), and the median duration of the glucocorticoid treatment was 13 months.

Sign In to Access Full Content

Don't have Access?

Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more

Subscribe for full-text access to content from 1998 forward and a host of useful features

Activate your current subscription (AMA members and current subscribers)

Purchase Online Access to this article for 24 hours

First Page Preview

View Large
/>
First page PDF preview

Figures

Tables

References

Correspondence

July 23, 2001
Marco Boscaro, MD; Luisa Barzon, MD; Nicoletta Sonino, MD
Arch Intern Med. 2001;161(14):1780. doi:.
July 23, 2001
Vasi Naganathan, FRACP; Philip Sambrook, FRACP
Arch Intern Med. 2001;161(14):1781. doi:.
CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).
Submit a Comment

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...
Articles Related By Topic
Related Topics
PubMed Articles
Jobs
JAMAevidence.com

Users' Guides to the Medical Literature
Osteoporosis

Users' Guides to the Medical Literature
A trial of sodium fluoride as secondary prevention against osteoporosis in postmenopausal women...

brightcove.createExperiences();